Close the retail pathway and build the treatment bridge at the same time

This resource is not an argument for leaving concentrated 7-OH on gas-station shelves. High-concentration commercial products can produce substantial opioid exposure, rapid physical dependence, compulsive redosing, clinically significant withdrawal, respiratory depression, and overdose. The public-health case for controlling them is strong, and the DEA deserves credit for moving on 7-OH, mitragynine pseudoindoxyl, MGM-15, and MGM-16.^E02E12

The argument is narrower, and harder to dismiss: control these products without abandoning the people who have already become dependent on them.

Enforcement moves at the speed of a Federal Register publication. Treatment capacity moves at the speed of credentialling, licensure, workforce training, and bed construction — which is to say, years. When those two clocks are this far out of phase, the gap between them is not an abstraction. It is filled by people in withdrawal making decisions at three in the morning.

The missing denominator

U.S. Poison Centers recorded 593 reports involving 7-OH in all of 2025 and 901 in the first six months of 2026. Among 7-OH-only reports, 38.8% were classified as serious, 63.8% were treated in a healthcare facility, and 20.5% were hospitalised.^E01

Those figures are not a prevalence estimate. They are an alarm bell with no denominator. They do not tell us how many people use 7-OH daily, how many dose every one to three hours, how many wake in withdrawal, or how many have never disclosed the product to a clinician. That missing denominator is precisely the population who will experience a sudden supply interruption as an acute medical problem.

Two predictable failures

First, capacity. Emergency departments and detoxification programmes will encounter people whose exposure does not appear on a routine opiate screen, whose product label may be unreliable, and whose withdrawal may not map neatly onto a familiar clock or a COWS score.^E25 If the default clinical reflex is “opioid dependence, send to residential,” we will build a waiting list — and a waiting list in acute withdrawal is a discharge to the street.

Second, substitution. This is the lethal one. A person whose tolerance developed on an inconsistently labelled retail product, and whose supply ends on a single day, may substitute counterfeit tablets or fentanyl and misjudge the replacement dose. The illicit opioid market is not a dependable taper. It is a dose-calculation exercise conducted with unknown units and lethal error bars.

A meaningful share of the people most at risk came to 7-OH from opioids — chronic pain patients tapered off prescriptions, and people using it as an unsupervised substitution agent to stay away from heroin and fentanyl. For that second group, badly dosed and unmonitored as it was, 7-OH was functioning as self-administered medication treatment. Remove it without offering a real replacement and you have not returned them to abstinence. You have returned them to the market they left.

The medicine is not the hard part

Buprenorphine works for this. A 2026 retrospective series of nine patients using purified 7-OH reported successful initiation and stabilisation in eight, using both standard and low-dose initiation, with no precipitated withdrawal reported in that cohort and eight reporting improvement at a median six-week follow-up.^E26 That is encouraging, not definitive — nine patients is nine patients.

But it can be started in an emergency department, a primary care office, or over video. It does not require a waiver. It does not require a residential bed. What it requires is that the clinician in front of the patient recognises what they are looking at and knows what to do. That is an education problem, and education is fast.

That is the whole thesis. Not that scheduling is wrong — that scheduling on its own is incomplete, and the missing half is something clinicians can supply ourselves, right now, without waiting for anyone's permission.

1. Add one question to your intake. Not “do you use kratom” — ask about pressed tablets, shots, gummies, films, and any product with a milligram figure on the label. Patients do not classify these as opioids and will not volunteer them.
2. Know that your urine drug screen is blind to this. A negative opiate immunoassay tells you nothing. Order the right assay, or do not order one at all.
3. Be willing to induct. The waiver is gone. If you hold a DEA registration you can prescribe buprenorphine. The most valuable thing you can be over the next six months is a clinician who does not refer this patient somewhere else.
4. Co-prescribe naloxone, every time. The acute risk is not the 7-OH. It is what the patient takes when the 7-OH runs out.
5. Do not default to residential. Reserve it for genuine indications. Level-of-care criteria are in the treatment module.

Five asks. None requires new statutory authority, and none is in tension with enforcement.

• Pair the enforcement announcement with a treatment announcement. The same press release, the same day, with a phone number in it.
• Fund naloxone distribution at the point of retail removal. The retailers being shut down know exactly who their customers are.
• Issue clinician guidance before the effective date, not after. HHS is capable of this in weeks.
• Protect research access. Schedule I placement makes the studies we most need — withdrawal course, treatment response, real-world product potency, high-dose human pharmacokinetics — dramatically harder to conduct. Build in a research pathway.
• Do not let the temporary order become permanent by inertia. Two years is enough time to generate the evidence that should have informed the decision. Use it.

You have a customer list of people who are physiologically dependent on a product you are about to stop selling. You know who they are.

There is exactly one honourable thing to do with that information: tell them, before the shelves empty, that what they will experience when they stop is opioid withdrawal, that it is treatable, and where to go. Put a treatment locator on the point-of-sale display. It costs nothing and it will matter more than anything else the industry does this year.

A platform-length post that fits inside LinkedIn’s character limit, a first comment carrying the sources, and a longer article for a newsletter or blog. Adapt them, sign with your own name, and change anything you do not personally stand behind. The point is volume: the more clinicians who say this publicly before the effective date, the more likely it is that the treatment half of the transition actually gets built.